Improvement in cardiac function and free fatty acid metabolism in a case of dilated cardiomyopathy with CD36 deficiency

Jpn Circ J. 2000 Sep;64(9):731-5. doi: 10.1253/jcj.64.731.

Abstract

A 27-year-old man diagnosed as having dilated cardiomyopathy (DCM) without myocardial accumulation of 123I-beta-methyl-iodophenylpentadecanoic acid, and he was found to have type I CD36 deficiency. This abnormality of cardiac free fatty acid metabolism was also confirmed by other methods: 18F-fluoro-2-deoxyglucose positron emission tomography, measurements of myocardial respiratory quotient and cardiac fatty acid uptake. Although the type I CD36 deficiency was reconfirmed after 3 months, the abnormal free fatty acid metabolism improved after carvedilol therapy and was accompanied by improved cardiac function. Apart from a cause-and-effect relationship, carvedilol can improve cardiac function and increase free fatty acid metabolism in patients with both DCM and CD36 deficiency.

Publication types

  • Case Reports

MeSH terms

  • Adrenergic beta-Antagonists / administration & dosage
  • Adult
  • CD36 Antigens / metabolism*
  • Carbazoles / administration & dosage
  • Cardiomyopathy, Dilated / diagnostic imaging
  • Cardiomyopathy, Dilated / metabolism*
  • Cardiomyopathy, Dilated / physiopathology
  • Carvedilol
  • Fatty Acids / pharmacokinetics
  • Fatty Acids, Nonesterified / metabolism*
  • Fluorodeoxyglucose F18 / pharmacokinetics
  • Heart Function Tests / methods*
  • Humans
  • Iodobenzenes / pharmacokinetics
  • Male
  • Propanolamines / administration & dosage
  • Radionuclide Imaging
  • Radiopharmaceuticals / pharmacokinetics

Substances

  • Adrenergic beta-Antagonists
  • CD36 Antigens
  • Carbazoles
  • Fatty Acids
  • Fatty Acids, Nonesterified
  • Iodobenzenes
  • Propanolamines
  • Radiopharmaceuticals
  • iodofiltic acid
  • Carvedilol
  • Fluorodeoxyglucose F18